Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia

Sponsor

Poitiers University Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT04910698

Collaborator

(none)

104

Enrollment

Location

Actual Duration (Months)

20.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

There is no specific recommendation about antimicrobial treatment length for documented infections in chemotherapy induced febrile neutropenia. The aim of this study was to compare long versus short antibiotic course for bloodstream infection treatment in acute myeloid leukemia patients during febrile neutropenia. This monocentric retrospective comparative study included all consecutive bloodstream infection episodes among acute myeloid leukemia patients with febrile neutropenia for 3 years (2017-2019). Episodes were classified regarding the length of antibiotic treatment, considered as short course if the treatment lasted ≤7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was ≤10 days and ≤14 days, respectively. The primary outcome was the number of bloodstream infection relapses in both groups within 30 days of antibiotic discontinuation.

Condition or Disease	Intervention/Treatment	Phase
Bloodstream Infection Acute Myeloid Leukemia Febrile Neutropenia	Drug: Antibiotic

Study Design

Study Type:

Observational

Actual Enrollment :

104 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia: a Retrospective Comparative Study

Actual Study Start Date :

Jan 1, 2020

Actual Primary Completion Date :

Jun 1, 2020

Actual Study Completion Date :

Jun 1, 2020

Arms and Interventions

Arm	Intervention/Treatment
Short course treatment Patients who received antibiotic for 7 or less days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.	Drug: Antibiotic Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
Long course treatment Patients who received antibiotic for more than 7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.	Drug: Antibiotic Antibiotic duration of treatment defined if the patient belonged to long course or short course group.

Arm

Intervention/Treatment

Short course treatment

Patients who received antibiotic for 7 or less days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.

Drug: Antibiotic

Antibiotic duration of treatment defined if the patient belonged to long course or short course group.

Long course treatment

Patients who received antibiotic for more than 7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.

Drug: Antibiotic

Antibiotic duration of treatment defined if the patient belonged to long course or short course group.

Outcome Measures

Primary Outcome Measures

Bloodstream infection relapses [within 30 days of antibiotic discontinuation]
The primary outcome was to compare the number of bloodstream infection relapses in both groups within 30 days of antibiotic discontinuation.

Secondary Outcome Measures

Mortality [within 30 days of antibiotic discontinuation]
Comparison of mortality rate within 30 days of antibiotic discontinuation
Epidemiology of bacteria [at baseline]
Distribution of bacteria responsible for bloodstream infection
Risk factors for relapses [within 30 days of antibiotic discontinuation]
Analyse of risk factors for bloodstream infection relapses